{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T23:57:31Z","timestamp":1781049451939,"version":"3.54.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.hoc.2025.07.008","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T06:14:51Z","timestamp":1762928091000},"page":"89-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Management of In-Transit Metastatic Melanoma"],"prefix":"10.1016","volume":"40","author":[{"given":"Matthew C.","family":"Perez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Zager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"36","key":"10.1016\/j.hoc.2025.07.008_bib1","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2025.07.008_bib2","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.hoc.2025.07.008_bib3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10434-999-0315-x","article-title":"Are locoregional cutaneous metastases in melanoma predictable?","volume":"6","author":"Borgstein","year":"1999","journal-title":"Ann Surg Oncol"},{"issue":"21","key":"10.1016\/j.hoc.2025.07.008_bib4","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1200\/JCO.2005.12.245","article-title":"The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes","volume":"23","author":"Pawlik","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2025.07.008_bib5","first-page":"472","article-title":"Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.hoc.2025.07.008_bib6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/CMR.0000000000000425","article-title":"Quality of life patient-reported outcomes for locally advanced cutaneous melanoma","volume":"28","author":"Weitman","year":"2018","journal-title":"Melanoma Res"},{"issue":"8","key":"10.1016\/j.hoc.2025.07.008_bib7","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.hoc.2025.07.008_bib8","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.hoc.2025.07.008_bib9","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2025.07.008_bib10","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.hoc.2025.07.008_bib11","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.hoc.2025.07.008_bib12","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1245\/s10434-019-07965-w","article-title":"The Prognosis and Natural History of In-Transit Melanoma Metastases at a High-Volume Centre","volume":"26","author":"Nan Tie","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2025.07.008_bib13","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1245\/ASO.2005.05.025","article-title":"Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy","volume":"12","author":"Pawlik","year":"2005","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2025.07.008_bib14","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1245\/s10434-014-4100-0","article-title":"In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy","volume":"22","author":"Read","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2025.07.008_bib15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/jso.2930440305","article-title":"Natural history and selective management of in transit melanoma","volume":"44","author":"Wong","year":"1990","journal-title":"J Surg Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2025.07.008_bib16","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/CMR.0000000000000666","article-title":"Staging 18F-FDG PET\/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases","volume":"30","author":"Holtkamp","year":"2020","journal-title":"Melanoma Res"},{"issue":"3","key":"10.1016\/j.hoc.2025.07.008_bib17","doi-asserted-by":"crossref","first-page":"e318","DOI":"10.3747\/co.27.6523","article-title":"Locoregional management of in-transit metastasis in melanoma: an Ontario Health (Cancer Care Ontario) clinical practice guideline","volume":"27","author":"Wright","year":"2020","journal-title":"Curr Oncol"},{"key":"10.1016\/j.hoc.2025.07.008_bib18","article-title":"Adjuvant radiation does not affect locoregional control following resection of melanoma satellitosis or in-transit disease","author":"Yaney","year":"2021","journal-title":"Am Surg"},{"issue":"9","key":"10.1016\/j.hoc.2025.07.008_bib19","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1245\/s10434-017-5883-6","article-title":"Sentinel Lymph Node Biopsy for Recurrent Melanoma: A Multicenter Study","volume":"24","author":"Beasley","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2025.07.008_bib20","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/0277-5379(82)90235-8","article-title":"Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions","volume":"18","author":"Wieberdink","year":"1982","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2025.07.008_bib21","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/00000658-195810000-00009","article-title":"Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit","volume":"148","author":"Creech","year":"1958","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.hoc.2025.07.008_bib22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00000658-196209000-00009","article-title":"An appraisal of cancer chemotherapy by regional perfusion","volume":"156","author":"Krementz","year":"1962","journal-title":"Ann Surg"},{"issue":"3205","key":"10.1016\/j.hoc.2025.07.008_bib23","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1126\/science.123.3205.984","article-title":"Action of p-[di(2-chloroethyl)]-amino-l-phenylalanine on Harding-Passey mouse melanoma","volume":"123","author":"Luck","year":"1956","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.hoc.2025.07.008_bib24","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/archsurg.139.11.1237","article-title":"Isolated limb perfusion for unresectable melanoma of the extremities","volume":"139","author":"Noorda","year":"2004","journal-title":"Arch Surg"},{"issue":"25","key":"10.1016\/j.hoc.2025.07.008_bib25","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1200\/JCO.2005.05.5152","article-title":"Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020","volume":"24","author":"Cornett","year":"2006","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2025.07.008_bib26","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3109\/02656736.2013.802374","article-title":"Long-term follow-up of 163 consecutive patients treated with isolated limb perfusion for in-transit metastases of malignant melanoma","volume":"29","author":"Olofsson","year":"2013","journal-title":"Int J Hyperthermia"},{"issue":"2","key":"10.1016\/j.hoc.2025.07.008_bib27","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jamcollsurg.2011.03.013","article-title":"Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution","volume":"213","author":"Raymond","year":"2011","journal-title":"J Am Coll Surg"},{"issue":"21","key":"10.1016\/j.hoc.2025.07.008_bib28","first-page":"13","article-title":"Role of Isolated Limb Perfusion in the Era of Targeted Therapies and Immunotherapy in Melanoma. A Systematic Review of The Literature","author":"Sevilla-Ortega","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.hoc.2025.07.008_bib29","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/(SICI)1098-2388(199804\/05)14:3<238::AID-SSU8>3.0.CO;2-9","article-title":"Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion","volume":"14","author":"Thompson","year":"1998","journal-title":"Semin Surg Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2025.07.008_bib30","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/jso.25886","article-title":"Isolated limb infusion: Institutional protocol and implementation","volume":"122","author":"Carr","year":"2020","journal-title":"J Surg Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2025.07.008_bib31","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/jso.23553","article-title":"Isolated limb infusion with melphalan and actinomycin D for melanoma: a systematic review","volume":"109","author":"Kroon","year":"2014","journal-title":"J Surg Oncol"},{"issue":"13","key":"10.1016\/j.hoc.2025.07.008_bib32","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1245\/s10434-017-6107-9","article-title":"Isolated Limb Infusion: A Single-Center Experience with Over 200 Infusions","volume":"24","author":"O\u2019Donoghue","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2025.07.008_bib33","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1245\/s10434-015-4969-2","article-title":"Australian Multicenter Study of Isolated Limb Infusion for Melanoma","volume":"23","author":"Kroon","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2025.07.008_bib34","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1245\/s10434-019-07288-w","article-title":"Long-Term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis","volume":"26","author":"Miura","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2025.07.008_bib35","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1245\/s10434-014-4072-0","article-title":"Burden of disease predicts response to isolated limb infusion with melphalan and actinomycin D in melanoma","volume":"22","author":"Muilenburg","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2025.07.008_bib36","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1016\/j.ejso.2020.06.040","article-title":"Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study","volume":"46","author":"Kenyon-Smith","year":"2020","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.hoc.2025.07.008_bib37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00003086-199101000-00002","article-title":"The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893","volume":"262","author":"Coley","year":"1991","journal-title":"Clin Orthop Relat Res"},{"issue":"4","key":"10.1016\/j.hoc.2025.07.008_bib38","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00000658-197410000-00029","article-title":"BCG immunotherapy of malignant melanoma: summary of a seven-year experience","volume":"180","author":"Morton","year":"1974","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.hoc.2025.07.008_bib39","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jaad.2009.12.013","article-title":"Intralesional agents in the management of cutaneous malignancy: a review","volume":"64","author":"Good","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.hoc.2025.07.008_bib40","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/jama.1994.03510360033032","article-title":"Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2","volume":"271","author":"Rosenberg","year":"1994","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.hoc.2025.07.008_bib41","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/sj.bjc.6601320","article-title":"Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases","volume":"89","author":"Radny","year":"2003","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2025.07.008_bib42","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1177\/1203475420988862","article-title":"Durability of Complete Response to Intralesional Interleukin-2 for In-Transit Melanoma","volume":"25","author":"Khoury","year":"2021","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"10.1016\/j.hoc.2025.07.008_bib43","first-page":"139","article-title":"Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells","volume":"5","author":"Nasi","year":"1999","journal-title":"Cytokines Cell Mol Ther"},{"issue":"3","key":"10.1016\/j.hoc.2025.07.008_bib44","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00008390-199606000-00008","article-title":"Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF","volume":"6","author":"Si","year":"1996","journal-title":"Melanoma Res"},{"issue":"9","key":"10.1016\/j.hoc.2025.07.008_bib45","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1097\/01.cad.0000231474.77159.e3","article-title":"Antisense-mediated melanoma inhibitor of apoptosis protein downregulation sensitizes G361 melanoma cells to cisplatin","volume":"17","author":"Mousavi-Shafaei","year":"2006","journal-title":"Anti Cancer Drugs"},{"issue":"7","key":"10.1016\/j.hoc.2025.07.008_bib46","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1245\/s10434-014-4169-5","article-title":"Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma","volume":"22","author":"Thompson","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2025.07.008_bib47","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/jso.24921","article-title":"Intralesional PV-10 for the treatment of in-transit melanoma metastases-Results of a prospective, non-randomized, single center study","volume":"117","author":"Read","year":"2018","journal-title":"J Surg Oncol"},{"issue":"25","key":"10.1016\/j.hoc.2025.07.008_bib48","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.hoc.2025.07.008_bib49","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1245\/s10434-018-6803-0","article-title":"Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience","volume":"25","author":"Perez","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2025.07.008_bib50","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jamcollsurg.2018.12.027","article-title":"Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience","volume":"228","author":"Louie","year":"2019","journal-title":"J Am Coll Surg"},{"issue":"2","key":"10.1016\/j.hoc.2025.07.008_bib51","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1245\/s10434-021-10910-5","article-title":"Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience","volume":"29","author":"Carr","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2025.07.008_bib52","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/CMR.0000000000000719","article-title":"The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials","volume":"31","author":"Olofsson Bagge","year":"2021","journal-title":"Melanoma Res"},{"key":"10.1016\/j.hoc.2025.07.008_bib53","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2022.03.041","article-title":"The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases - A multicenter cohort study","volume":"169","author":"Holmberg","year":"2022","journal-title":"Eur J Cancer. Jul"},{"key":"10.1016\/j.hoc.2025.07.008_bib54","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2021.04.032","article-title":"Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases","volume":"152","author":"Zaremba","year":"2021","journal-title":"Eur J Cancer"},{"issue":"17","key":"10.1016\/j.hoc.2025.07.008_bib55","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma","volume":"36","author":"Chesney","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2025.07.008_bib56","first-page":"Jco2200343","article-title":"Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma","volume":"23","author":"Chesney","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T06:15:24Z","timestamp":1762928124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858825000954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0889858825000954"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2025.07.008","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of In-Transit Metastatic Melanoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2025.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}